p53 Monoclonal Antibody (SP5) | Invitrogen MA5-16387 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

p53 Monoclonal Antibody (SP5)

catalog :

MA5-16387

quantity :

500 µL

price :

US 446

clonality :

monoclonal

host :

domestic rabbit

conjugate :

nonconjugated

clone name :

SP5

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

citations: 14

Reference
Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher
Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, Shariat S, et al. Quantitative apparent diffusion coefficient measurements obtained by 3-Tesla MRI are correlated with biomarkers of bladder cancer proliferative activity. PLoS ONE. 2014;9:e106866 pubmed publisher
Tsou Y, Huang H, Wang T, Tai C, Chen C, Chen C. Evaluation of correlation of cell cycle proteins and Ki-67 interaction in paranasal sinus inverted papilloma prognosis and squamous cell carcinoma transformation. Biomed Res Int. 2014;2014:634945 pubmed publisher
Khandakar B, Mathur S, Kumar L, Kumar S, Datta Gupta S, Iyer V, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:401245 pubmed publisher
Staff S, Tolonen T, Laasanen S, Mecklin J, Isola J, Maenpaa J. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Int J Gynecol Pathol. 2014;33:309-16 pubmed publisher
Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012;7:124 pubmed publisher
Meijer D, de Jong D, Pansuriya T, van den Akker B, Picci P, Szuhai K, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51:899-909 pubmed publisher
Meijer Jorna L, van der Loos C, Teeling P, de Boer O, Florquin S, van der Horst C, et al. Proliferation and maturation of microvessels in arteriovenous malformations--expression patterns of angiogenic and cell cycle-dependent factors. J Cutan Pathol. 2012;39:610-20 pubmed publisher
Perisanidis C, Perisanidis B, Wrba F, Brandstetter A, El Gazzar S, Papadogeorgakis N, et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med. 2012;41:40-6 pubmed publisher
Sciuscio D, Diserens A, van Dommelen K, Martinet D, Jones G, Janzer R, et al. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res. 2011;17:255-66 pubmed publisher
Abdelzaher E, El Gendi S, Yehya A, Gowil A. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25:707-13 pubmed publisher
Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma. Appl Immunohistochem Mol Morphol. 2011;19:28-32 pubmed publisher
Wang R, Wen M, Wang J, Ho S, Jan Y. Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and literature review. Int J Surg Pathol. 2011;19:99-103 pubmed publisher
Song Z, Wang Y, Xie L, Zang X, Yin H. Expression of senescence-related genes in human corneal endothelial cells. Mol Vis. 2008;14:161-70 pubmed

product information

Product Type :

Antibody

Product Name :

p53 Monoclonal Antibody (SP5)

Catalog # :

MA5-16387

Quantity :

500 µL

Price :

US 446

Clonality :

Monoclonal

Host :

Rabbit

Reactivity :

Human

Applications :

Flow Cytometry: 1:200, Immunocytochemistry: 1:100, Immunofluorescence: 1:100, Immunohistochemistry (Paraffin): 1:100, Western Blot: 1:1000

Species :

Human

Clone :

SP5

Isotype :

IgG

Storage :

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Description :

The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.

Immunogen :

Recombinant human full length wild type p53 protein.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1:200, Immunocytochemistry: 1:100, Immunofluorescence: 1:100, Immunohistochemistry (Paraffin): 1:100, Western Blot: 1:1000

Aliases :

antigen NY-CO-13; bbl; BCC7; bfy; bhy; Cellular tumor antigen p53; Cys 51 Stop; EGK_08142; FLJ92943; HGNC11998; I79_002739; LFS1; Li-Fraumeni syndrome; mutant p53; mutant tumor protein 53; OTTMUSP00000006194; p44; P53; p53 cellular tumor antigen; p53 tumor suppressor; p53 tumor suppressor phosphoprotein; phosphoprotein p53; Tp53; tp53.L; transformation related protein 53; transformation-related protein 53; Trp248; TRP53; tumor protein 53; tumor protein p53; tumor protein p53 (Li-Fraumeni syndrome); tumor protein p53 L homeolog; Tumor suppressor p53; tumor suppressor p53 phosphoprotein; tumor suppressor protein p53; tumor supressor p53; Tumour Protein p53; XELAEV_180196761mg; Xp53; Xrel3